Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
نویسنده
چکیده
Ferric citrate hydrate was recently approved in Japan as an oral phosphate binder to be taken with food for the control of hyperphosphatemia in patients with chronic kidney disease (CKD). The daily therapeutic dose is about 3 to 6 g, which comprises about 2 to 4 g of citrate. Oral citrate solubilizes aluminum that is present in food and drinking water, and opens the tight junctions in the intestinal epithelium, thereby increasing aluminum absorption and urinary excretion. In healthy animals drinking tap water, oral citrate administration increased aluminum absorption and, over a 4-week period, increased aluminum deposition in brain and bone by about 2- and 20-fold, respectively. Renal excretion of aluminum is impaired in patients with chronic kidney disease, thereby increasing the risk of toxicity. Based on human and animal studies it can be surmised that patients with CKD who are treated with ferric citrate hydrate to control hyperphosphatemia are likely to experience enhanced absorption of aluminum from food and drinking water, thereby increasing the risk of aluminum overload and toxicity.
منابع مشابه
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
BACKGROUND AND OBJECTIVES Ferric citrate hydrate is a novel iron-based phosphate binder being developed for hyperphosphatemia in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A phase 3, multicenter, randomized, double blind, placebo-controlled study investigated the efficacy and safety of ferric citrate hydrate in nondialysis-dependent patients with CKD. Starting in April o...
متن کاملAdministration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
BACKGROUND/AIM Dietary phosphate intake and vitamin D receptor activator (VDRA) regulate fibroblast growth factor 23 (FGF23); iron may modulate FGF23 metabolism. We aimed to determine whether oral iron supplementation influences serum FGF23 concentration in hemodialysis (HD) patients, while excluding the effect of dietary phosphate intake. METHODS This prospective study enrolled 27 maintenanc...
متن کاملIron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Increased cardiovascular morbidity and mortality has been associated with the hyperphosphatemia seen in patients with end-stage chronic kidney disease (CKD). Oral phosphate binders are prescribed in these patients to prevent intestinal absorption of dietary phosphate and reduce serum phosphate. In prospective observational cohorts they have shown to decrease all-cause and cardiovascular mortali...
متن کاملA randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
BACKGROUND JTT-751 is a novel phosphate binder containing ferric citrate as the active ingredient. METHODS In this Phase 3, multicenter, randomized, open-label, parallel-group study, we compared the efficacy and safety of JTT-751 and sevelamer hydrochloride in patients undergoing hemodialysis. A total of 230 patients with a serum phosphate ≥1.97 and <3.23 mmol/L were randomized to JTT-751 (do...
متن کاملEfficacy of ferric citrate as a phosphate-binding agent in end-stage renal disease.
Sir, I read with great interest the article by Yang et al. w1x, describing the role of ferric citrate as a phosphate binder in haemodialysis patients. Dr Yang and colleagues have presented their data (Table 3), which demonstrate convincingly that ferric citrate lowers serum phosphate, though not as significantly as calcium carbonate. However, the presentation of statistically significant data c...
متن کامل